Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Western Digital Corp (WDC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Western Digital Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $285.68 (market cap $39.89B), while Western Digital Corp trades at $557.73 (market cap $200.81B). The key difference: Western Digital Corp is far larger — about 5× Alnylam Pharmaceuticals, Inc.'s market cap, and Western Digital Corp pays a 0.1% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WDC | |
|---|---|---|
Market Cap | $39.89B | $200.81B |
Sector | Health | Technology |
52-Week High | $491.22 | $746.23 |
52-Week Low | $278.09 | $66.14 |
Enterprise Value | $38.15B | $199.15B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Western Digital (WDC) trades at $582.59, up 0.78% on the day, with a neutral technical signal and bullish moving averages. The company has beaten EPS estimates for three consecutive quarters, with Q2 2026 expected at $3.29. Strong profitability metrics include a 55.07% net income margin and 37.73% ROE. Recent news highlights AI-driven storage demand and analyst optimism, including a Wells Fargo price target hike on July 10, 2026.
WDC's outlook is positive due to AI infrastructure tailwinds and consistent earnings beats, but risks include sector volatility and premium valuations. The consensus price target of $610.86 suggests modest upside, supported by 72% analyst buy ratings. Investors should monitor execution against growth forecasts and competitive dynamics in the memory market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
